These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 36831716)

  • 1. Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Antipsychotics-An Observational Study.
    Miron AA; Petric PS; Teodorescu A; Ifteni P; Chele G; Szalontay AS
    Brain Sci; 2023 Jan; 13(2):. PubMed ID: 36831716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time to rehospitalization in patients with bipolar mania discharged on long-acting injectable or oral antipsychotics.
    Lin CH; Chan HY; Hsu CC; Chen FC
    J Affect Disord; 2021 Jan; 279():292-298. PubMed ID: 33096327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.
    Kishimoto T; Robenzadeh A; Leucht C; Leucht S; Watanabe K; Mimura M; Borenstein M; Kane JM; Correll CU
    Schizophr Bull; 2014 Jan; 40(1):192-213. PubMed ID: 23256986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics: A Nationwide Real-World Study in Japan.
    Onitsuka T; Okada T; Hasegawa N; Tsuboi T; Iga JI; Yasui-Furukori N; Yamada N; Hori H; Muraoka H; Ohi K; Ogasawara K; Ochi S; Takeshima M; Ichihashi K; Fukumoto K; Iida H; Yamada H; Furihata R; Makinodan M; Takaesu Y; Numata S; Komatsu H; Hishimoto A; Kido M; Atake K; Yamagata H; Kikuchi S; Hashimoto N; Usami M; Katsumoto E; Asami T; Kubota C; Matsumoto J; Miura K; Hirano Y; Watanabe K; Inada K; Hashimoto R
    J Clin Psychopharmacol; 2023 Jul-Aug 01; 43(4):365-368. PubMed ID: 37216369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic.
    Pilon D; Joshi K; Tandon N; Lafeuille MH; Kamstra RL; Emond B; Lefebvre P
    Patient Prefer Adherence; 2017; 11():619-629. PubMed ID: 28356723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics.
    Misawa F; Kishimoto T; Hagi K; Kane JM; Correll CU
    Schizophr Res; 2016 Oct; 176(2-3):220-230. PubMed ID: 27499361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort.
    Guinart D; Taipale H; Rubio JM; Tanskanen A; Correll CU; Tiihonen J; Kane JM
    Schizophr Bull; 2021 Oct; 47(6):1621-1630. PubMed ID: 34013325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination Therapy of Long-Acting Injectable Second-Generation Antipsychotics and Oral Antipsychotics: A Retrospective Chart Review and Prescribers' Attitude Survey.
    Misawa F; Amemiya A; Fujii Y; Takeuchi H
    J Clin Psychopharmacol; 2022 Jan-Feb 01; 42(1):81-86. PubMed ID: 34668878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics and Suicide and All-Cause Mortality in Patients With Newly Diagnosed Schizophrenia.
    Huang CY; Fang SC; Shao YJ
    JAMA Netw Open; 2021 May; 4(5):e218810. PubMed ID: 33974056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge.
    Doshi JA; Pettit AR; Stoddard JJ; Zummo J; Marcus SC
    J Clin Psychopharmacol; 2015 Aug; 35(4):442-6. PubMed ID: 26075492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics on Time to Rehospitalization Within 1 Year of Discharge in Elderly Patients With Schizophrenia.
    Lin CH; Chen FC; Chan HY; Hsu CC
    Am J Geriatr Psychiatry; 2020 Jan; 28(1):23-30. PubMed ID: 31481273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
    Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
    J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to rehospitalization in involuntarily hospitalized individuals suffering from schizophrenia discharged on long-acting injectable antipsychotics or oral antipsychotics.
    Lin CH; Chan HY; Wang FC; Hsu CC
    Ther Adv Psychopharmacol; 2022; 12():20451253221079165. PubMed ID: 35340566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting Injectable Antipsychotics in First-episode Schizophrenia.
    Jeong HG; Lee MS
    Clin Psychopharmacol Neurosci; 2013 Apr; 11(1):1-6. PubMed ID: 23678347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia.
    Fang SC; Huang CY; Shao YJ
    J Clin Psychiatry; 2022 Jun; 83(4):. PubMed ID: 35649156
    [No Abstract]   [Full Text] [Related]  

  • 17. [Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature].
    Graffino M; Montemagni C; Mingrone C; Rocca P
    Riv Psichiatr; 2014; 49(3):115-23. PubMed ID: 25000887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications.
    Aggarwal NK; Sernyak MJ; Rosenheck RA
    J Clin Psychopharmacol; 2012 Jun; 32(3):323-8. PubMed ID: 22544006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life.
    Montemagni C; Frieri T; Rocca P
    Neuropsychiatr Dis Treat; 2016; 12():917-29. PubMed ID: 27143893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia.
    Sathienluckana T; Tiangpattanawong P; Chaiyasukthananoan K; Jittayanan P; Sawetwangsing H; Puchsaka P
    Schizophr Res Treatment; 2021; 2021():8403986. PubMed ID: 34868682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.